IMPORTANCE In clinical guidelines, overt and subclinical thyroid dysfunction are mentioned as causal and treatable factors for cognitive decline. However, the scientific literature on these associations shows inconsistent findings.

OBJECTIVE To assess cross-sectional and longitudinal associations of baseline thyroid dysfunction with cognitive function and dementia.

DESIGN, SETTING, AND PARTICIPANTS This multicohort individual participant data analysis assessed 114,267 person-years (median, 1.7-11.3 years) of follow-up for cognitive function and 525,222 person-years (median, 3.8-15.3 years) for dementia between 1989 and 2017. Analyses on cognitive function included 21 cohorts comprising 38,144 participants. Analyses on dementia included eight cohorts with a total of 2033 cases with dementia and 44,573 controls. Data analysis was performed from December 2016 to January 2021.

EXPOSURES Thyroid function was classified as overt hyperthyroidism, subclinical hyperthyroidism, euthyroidism, subclinical hypothyroidism, and overt hypothyroidism based on uniform thyrotropin cutoff values and study-specific free thyroxine values.

MAIN OUTCOMES AND MEASURES The primary outcome was global cognitive function, mostly measured using the Mini-Mental State Examination. Executive function, memory, and dementia were secondary outcomes. Analyses were first performed at study level using multivariable linear regression and multivariable Cox regression, respectively. The studies were combined with restricted maximum likelihood meta-analysis. To overcome the use of different scales, results were transformed to standardized mean differences. For incident dementia, hazard ratios were calculated.

RESULTS Among 74,565 total participants, 66,567 (89.3%) participants had normal thyroid function, 577 (0.8%) had overt hyperthyroidism, 2557 (3.4%) had subclinical hyperthyroidism, 4167 (5.6%) had subclinical hypothyroidism, and 697 (0.9%) had overt hypothyroidism. The study-specific median age at baseline varied from 57 to 93 years; 42,847 (57.5%) participants were women. Thyroid dysfunction was not associated with global cognitive function; the largest differences were observed between overt hypothyroidism and euthyroidism—cross-sectionally (−0.06 standardized mean difference in score; 95% CI, −0.20 to 0.08; P = .40) and longitudinally (0.11 standardized mean difference higher decline per year; 95% CI, −0.01 to 0.23; P = .09). No consistent associations were observed between thyroid dysfunction and executive function, memory, or risk of dementia.

CONCLUSIONS AND RELEVANCE In this individual participant data analysis of more than 74,000 adults, subclinical hypothyroidism and hyperthyroidism were not associated with cognitive function, cognitive decline, or incident dementia. No rigorous conclusions can be drawn regarding the role of overt thyroid dysfunction in risk of dementia. These findings do not support the practice of screening for subclinical thyroid dysfunction in the context of cognitive decline in older adults as recommended in current guidelines.
thyroid dysfunction is considered a potentially reversible cause of cognitive decline; hence, thyroid function screening tests are described in guidelines as an essential component of the workup for the diagnosis of dementia.1-3 Thyroid dysfunction is frequently observed in individuals with suspected dementia.4 However, the outcomes of treatment of overt hypothyroidism and hyperthyroidism and subclinical hyperthyroidism on cognitive function are not fully clarified.5-7 For subclinical hypothyroidism, 4 of 5 recent randomized clinical trials and a meta-analysis on levothyroxine treatment did not find evidence for an improvement in cognitive function.8-13 Moreover, meta-analyses of observational studies have yielded inconsistent results on associations of subclinical and overt thyroid dysfunction with cognitive impairment and risk of dementia.14-17 An individual participant data analysis of cohort studies might help clarify the conflicting results of previous studies, as it allows for uniform definitions of thyroid dysfunction and it can assess the differential associations by age groups, sex, and thyroid medication in subgroup analyses.18 In the present study, we investigated cross-sectional and longitudinal associations of thyroid dysfunction with cognitive function and dementia in an individual participant data analysis of multiple cohorts.

Methods

Study Population
We first approached the coordinating center of the Thyroid Studies Collaboration, a collaborative project of 25 existing longitudinal studies with information on thyroid status.18 The Medical Ethics Committee of the Leiden University Medical Center waived the need for review owing to the retrospective nature of the study using only previously collected data; no individuals underwent interventions for the present study. Each participant gave informed consent to the original study they participated in, which was oral or written depending on the original study design and legislation at the time of data collection. All 15 Thyroid Studies Collaboration cohorts that had collected data on cognitive function or dementia joined the project. The study designs for all cohorts participating in the current study have been described previously in more detail.19-37 We approached 14 additional cohorts that were extracted from 4 recent meta-analyses on subclinical thyroid dysfunction and cognitive function or dementia.14-17 Six of these cohorts consented to collaborating and sharing data.34-39 Lastly, we included publicly available data of the National Health and Nutrition Examination Survey waves of 1999 to 2002 and 2011 to 2012, which simultaneously collected thyroid and cognitive function among many other parameters.40

Thyroid Function
Thyroid dysfunction was determined biochemically by measurements of thyrotropin and free thyroxine (FT4) concentrations in all cohorts. Cohort-specific cutoff values were used for FT4 levels (eTable 1 in the Supplement). In accordance with previous projects in the Thyroid Studies Collaboration, participants were classified as euthyroid if thyrotropin level was 0.45 to 4.49 mIU/L.18 Overt hyperthyroidism was defined as a thyrotropin level less than 0.45 mIU/L and FT4 level above the reference range. Subclinical hyperthyroidism was defined as a thyrotropin level less than 0.45 mIU/L and FT4 levels within the reference range, or only as thyrotropin level less than 0.45 mIU/L in absence of an FT4 measurement (n = 896 among 10 cohorts) because overt hyperthyroidism is rare.41 A combination of thyrotropin level of 4.50 to 20 mIU/L and FT4 levels within the reference range was defined as subclinical hypothyroidism. Individuals who had missing FT4 measurements with mildly elevated thyrotropin levels (4.50-20 mIU/L) were considered subclinically hypothyroid (n = 523 among 8 cohorts) because chances of overt hypothyroidism in this patient category are low.41 A thyrotropin level of 20 mIU/L or greater or thyrotropin level of 4.50 mIU/L or greater combined with FT4 levels below the reference range was defined as overt hypothyroidism.

Cognitive Function
The primary outcome was global cognitive function measured by Mini-Mental State Examination (MMSE), Modified Mini-Mental State (3MS), or Severe Cognitive Impairment Rating Scale.52-54 A difference of 1 point in MMSE score is considered the minimal clinically important difference in individuals without dementia.55 Executive function and memory were secondary outcomes. For executive function, various tests were used: Digit Symbol Substitution Test, Trail Making Test B, Letter Digit Substitution Test (LDST), Executive Interview 15, and Ruff Figural Fluency Test.46-50 The minimal clinically important difference for executive function was defined as a difference of 4 points in LDST.51 Memory was measured using either Rey’s Auditory Verbal Learning Test (also referred to as Word Learning Test or Verbal Learning Test), Digit Span Test, or Visual Association Test.52-55 No minimal clinically important difference for memory tests was found in the literature.

Dementia
Depending on the study design, dementia was diagnosed either in a clinical setting or at a research center. The diagnosis was, at least in part, based on clinical presentation. Studies in which dementia diagnosis was based only on a cutoff point for the

Key Points

Question Is thyroid dysfunction associated with cognitive decline?

Findings In this individual participant data analysis of 23 cohorts including 74 565 participants with cognitive function and/or dementia measurements, subclinical thyroid dysfunction was not associated with global cognitive function at baseline (standardized mean difference, −0.02 for subclinical hyperthyroidism and 0.05 for subclinical hypothyroidism) or annual decline (standardized mean difference, −0.02 for subclinical hyperthyroidism and −0.00 for subclinical hypothyroidism).

Meaning These findings do not support the need for screening for subclinical thyroid dysfunction for prevention of cognitive decline or dementia.
MMSE were excluded from this analysis because cognitive function tests are insufficient to diagnose dementia. Prevalence of dementia at baseline was available for 11 cohorts; 431 participants had a diagnosis of dementia at baseline, but only 78 of them were classified as noneuthyroid. Owing to the small number of participants with thyroid dysfunction at baseline, no cross-sectional analyses for dementia were performed.

**Statistical Analyses**

We used a 2-stage individual participant data analysis approach, which accommodates uniform definitions and analyses for each cohort while keeping complexity to a minimum. The first stage consisted of study-level analysis of thyroid dysfunction and cognitive function or dementia conducted on the original data sets with participant-level data. In the second stage, the effect estimates from the first stage were pooled using a random-effects model based on restricted maximum likelihood. Heterogeneity across studies was quantified using the $I^2$ statistic: less than 40% was considered low heterogeneity; 40% to 75%, moderate heterogeneity; and greater than 75%, high heterogeneity.

For both the cross-sectional and longitudinal analyses between thyroid dysfunction and cognitive function, we used multivariable linear regression models. To facilitate combination of different scales, the results were transformed to standardized mean differences. In the prospective analysis of cognitive decline, we calculated the difference between the last available measure of cognitive function and baseline cognitive function. The difference was divided by the follow-up time in years to obtain an annual decline, irrespective of duration of follow-up. The annual decline was subsequently standardized, resulting in a standardized mean difference in annual change in cognitive function allowing comparison of changes over time.

The risk of developing dementia during follow-up was assessed using Cox regression models. In these analyses, participants with dementia at baseline were excluded. For studies without precise registration of the date of dementia diagnosis, it was assumed that dementia developed halfway between the registration date and the last date that absence of dementia was ascertained.

Thyroid dysfunction (overt hyperthyroidism, subclinical hyperthyroidism, subclinical hypothyroidism, and overt hypothyroidism) was included as a categorical variable with the euthyroid group serving as reference. All analyses were adjusted for age and sex. The longitudinal analyses of cognitive decline were adjusted for baseline cognitive function. Pre-specified subgroup analyses were performed by stratification and interaction analysis for sex and for age younger or older than 75 years. Additional analyses were performed with adjustment for educational attainment, though this variable was not available in all cohorts. In sensitivity analyses, participants with missing $FT_4$ measurements in the subclinical hyperthyroid and subclinical hypothyroid groups were excluded, as were those who used antithyroid medication or thyroid hormone replacement therapy at baseline. Furthermore, we assessed robustness of the associations by pooling the estimates using fixed-effect models and by excluding studies with strata of fewer than 10 participants. To assess whether effects were dependent on degree of disruption of thyrotropin, analyses were repeated with thyrotropin categories of less than 0.10 mIU/L, 0.10 to 0.44 mIU/L, 4.5 to 6.9 mIU/L, 7.0 to 10 mIU/L, and greater than 10 mIU/L, in which participants with thyrotropin between 0.45 and 4.49 mIU/L served as reference. Lastly, instead of using biochemical cutoff points, thyrotropin and $FT_4$ were analyzed continuously across the full range with cognitive function. Thyrotropin was transformed using the natural logarithm; for both natural log-transformed thyrotropin and $FT_4$, models were constructed per standard deviation. Continuous models were performed minimally adjusted by age and sex and with additional adjustment for educational attainment. For sensitivity purposes, the analyses were also conducted excluding the participants who used antithyroid medication or thyroid hormone replacement therapy at baseline. Cohorts with greater than 10% missing measurements for $FT_4$ were excluded for the continuous analyses on $FT_4$. All $P$ values were 2-tailed; statistical significance was set at $P < .05$.

Study-level analyses were performed using SPSS Statistics, version 25 (IBM). Effect estimates were pooled and summarized in forest plots using R, version 3.6.1 and metafor package (R Foundation for Statistical Computing). This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.

**Results**

**Population Characteristics**

Individual participant data on thyroid function and cognitive function and/or dementia were provided by 23 cohorts comprising 74,565 participants. At baseline, 66,567 (89.3%) participants were biochemically classified as euthyroid, 577 (0.8%) as overtly hyperthyroid, 2,557 (3.4%) as subclinically hyperthyroid, 4,167 (5.6%) as subclinically hypothyroid, and 697 (0.9%) as overtly hypothyroid (eTable 1 in the Supplement). The study-specific median age at baseline varied from 57 to 93 years; 42,847 (57.5%) participants were women.

A total of 38,144 participants from 21 cohorts provided data on a measure of cognitive function (Table). The median age varied from 58 to 93 years, and 18,089 (47.4%) participants were women. Follow-up for cognitive decline was available for 14 cohorts, with a median follow-up duration varying from 1.7 to 11.3 years, accumulating 114,267 person-years.

Eight cohorts provided follow-up for dementia incidence on 46,606 participants (eTable 2 in the Supplement). Among these participants, 28,820 (61.8%) were women, and the median age at baseline was between 57 and 85 years. During follow-up, 2,033 (4.4%) cases of incident dementia were identified. Median follow-up duration ranged from 3.8 to 15.3 years, accumulating 525,222 person-years.

**Thyroid Dysfunction and Global Cognitive Function**

Cross-sectionally, thyroid dysfunction was not associated with global cognitive function among 18 cohorts (Figure 1; eFigure 1 in the Supplement). The largest observed difference was
Table. Baseline Characteristics of the 38,144 Participants With Cognitive Function Measurements in Included Studies

| Source                | Location       | Population description                  | Baseline, y | No. | Age, median (range), y | No. (%) | Cognitive function |
|-----------------------|----------------|----------------------------------------|-------------|-----|------------------------|----------|--------------------|
|                       |                |                                        |             |     |                        |          | Thalidomide users  |
|                       |                |                                        |             |     |                        |          | Follow-up duration, y |
|                       |                |                                        |             |     |                        |          |                    |
|                       |                |                                        |             |     |                        |          | Scales             |
|                       |                |                                        |             |     |                        |          | Score, b mean (SD) |
|                       |                |                                        |             |     |                        |          |                    |
|                       |                |                                        |             |     |                        |          |                    |
| Europe                |                |                                        |             |     |                        |          |                    |
| BELFRAIL cohort study | Belgium        | Adults aged ≥80 y                      | 2008-2009   | 523 | 84 (80-102)            | 193 (36.9) | MMSE 26 (4.0)      |
|                       |                |                                        |             |     |                        |          | 1.7 (0.5-2.3)      |
| BETS                  | England        | Community-dwelling adults aged ≥65 y   | 2002-2004   | 5845 | 72 (65-98)             | 2873 (49.2) | MMSE 28 (2.2) |
|                       |                |                                        |             |     |                        |          | 0.0 (2.2)          |
| CFAS                  | England and Wales | Adults aged ≥64 y             | 1991-1992   | 1015 | 73 (64-94)            | 497 (49.0) | MMSE 28 (2.0) |
|                       |                |                                        |             |     |                        |          | 2.0 (1.9-2.6)     |
| InCHIANTI Study       | Italy          | Community-dwelling adults             | 1998-2000   | 1187 | 71 (21-102)           | 521 (43.9) | MMSE 25 (4.8) |
|                       |                |                                        |             |     |                        |          | 9.0 (2.8-10.0)    |
| LASA                  | The Netherlands | Adults aged ≥65 y                    | 1995-1997   | 1266 | 75 (65-89)            | 616 (48.7) | MMSE, WLT 27 (3.1) |
|                       |                |                                        |             |     |                        |          | 9.9 (2.3-20.8)    |
| Leiden 85-plus Study  | The Netherlands | Adults aged 85 y                     | 1997-1999   | 557  | 85                     | 188 (33.8) | MMSE, LDST, VLT 24 (6.3) |
|                       |                |                                        |             |     |                        |          | 5.0 (1.0-5.0)     |
| LLS                   | The Netherlands | Long-lived siblings                  | 2002-2005   | 776  | 93 (89-103)           | 308 (39.7) | MMSE 24 (5.1) |
|                       |                |                                        |             |     |                        |          | 0                  |
| Paquid study          | France         | Community-dwelling adults aged ≥65 y  | 1989-1990   | 407  | 75 (66-94)            | 173 (42.5) | MMSE, DSST, VLT 26 (3.5) |
|                       |                |                                        |             |     |                        |          | 11.3 (1.5-27.0)   |
| PREVEND Study         | The Netherlands | Adults                                | 2003-2006   | 864  | 58 (35-82)            | 493 (57.1) | RFFT, VAT 64 (25.0) |
|                       |                |                                        |             |     |                        |          | 5.2 (0.8-7.8)     |
| PROSPER               | The Netherlands, Ireland, Scotland | Older community-dwelling adults aged 70-79 y with high cardiovascular risk | 1998-1999 | 5775 | 75 (69-83) | 2791 (48.3) | MMSE, LDST, WLT 28 (1.5) |
|                       |                |                                        |             |     |                        |          | 3.3 (0.8-4.0)     |
| Rotterdam Study       | The Netherlands | Adults aged ≥55 y                     | 1989-1992   | 1875 | 69 (55-93)            | 720 (38.4) | MMSE 28 (1.7) |
|                       |                |                                        |             |     |                        |          | 10.8 (1.5-21.7)   |
| SHIP                  | Germany        | Adults                                | 2002-2006   | 1329 | 69 (60-88)            | 682 (51.3) | MMSE 28 (3.2) |
|                       |                |                                        |             |     |                        |          | 5.6 (4.3-8.8)     |
| North America         |                |                                        |             |     |                        |          |                    |
| CHS                   | US             | Community-dwelling adults with Medicare eligibility | 1994-1998   | 3991 | 74 (64-98)            | 1635 (41.0) | DSST 90 (9.9) |
|                       |                |                                        |             |     |                        |          | 5.9 (0.9-7.0)     |
| HABC Study            | US             | Community-dwelling adults aged 70-79 y with Medicare eligibility | 1999-2000   | 2488 | 75 (71-82)            | 1208 (48.6) | DSST 90 (8.9) |
|                       |                |                                        |             |     |                        |          | 8.0 (2.0-13.0)    |
| MMC                   | Mexico         | Geriatric outpatients with and without dementia | 2004       | 156  | 79 (58-98)            | 49 (31.4)  | MMSE 15 (6.5) |
|                       |                |                                        |             |     |                        |          | 0                  |
| MrOS Study            | US             | Community-dwelling men aged ≥65 y      | 2000-2002   | 1600 | 73 (65-99)            | 1600 (100) | DSST 42 (18.3) |
|                       |                |                                        |             |     |                        |          | 0                  |
| NHANES 1999-2002      | US             | Adults                                | 1999-2002   | 853  | 70 (60-85)            | 416 (48.8) | DSST 45 (17.6) |
|                       |                |                                        |             |     |                        |          | 0                  |
| NHANES 2011-2012      | US             | Adults                                | 2011-2012   | 434  | 68 (60-80)            | 220 (50.7) | DSST, WLT 45 (17.6) |
|                       |                |                                        |             |     |                        |          | 0                  |

(continued)
Table. Baseline Characteristics of the 38 144 Participants With Cognitive Function Measurements in Included Studies (continued)

| Source | Location | Participant description | No. (%) | Age, median (range), y | No. (% | Age, median (range), y | Thyroid medication users | Follow-up duration, c | Cognitive function Asssociation of Thyroid Dysfunction With Cognitive Function |
|--------|----------|-------------------------|---------|------------------------|---------|------------------------|-----------------------|----------------------|------------------------------------------------|
| HIMS Australia | Men aged ≥65 y | 2001-2004 | 3168 | 76 (71-89) | 3168 (100) | 0 | 2897 (91.4) | 112 (3.5) | MMSE | 28 (1.3) | 0 |
| KLOSCAD Republic of Korea | Adults aged ≥60 y | 2010-2017 | 3854 | 70 (61-109) | 1702 (44.2) | 2152 (55.8) | 3476 (90.2) | NA | SCIRS, TMT, DST | (70-96) | 2 (1.1) | 179 (98.9) | 154 (85.1) | NA | MMSE, TMT, DST | 24 (3.9) | 0 | Overall |
| Asia | 21 Cohorts | 1989-2017 | 38 144 | 74 (21-109) | 74 (21-109) | 0 | 20 055 | 18 (0.9) | 33118 (87.1) | 1670 (5.3) | TMT, MMSE | 24 (0.7) | 0 |

Abbreviations: BETS, Birmingham Elderly Thyroid Study; CFAS, Cognitive Function and Aging Study; CHS, Cardiovascular Health Study; DSST, Digit Symbol Substitution Test; DST, Digit Span Test; EXIT 15, 15-item Executive Function Test; LDST, Longitudinal Digit Symbol Test; MMSE, Mini-Mental State Examination; SCIRS, Severe Cognitive Impairment Rating Scale; TMT, Trail Making Test; VAT, Visual Association Test; VLT, Verbal Learning Test; WLT, Word Learning Test.

- We used a common definition for biochemical euthyroidism of thyrotropin level of 0.45 to 4.49 mIU/L, resulting in different numbers from previous reports.
- Test scores are shown for global cognitive function tests. If no global cognitive function test scores were provided, executive function test scores were shown.
- Follow-up years for participants who had a follow-up measurement for cognitive function.
- Data on baseline medication use (thyroid replacement therapy, antithyroid drugs) were unavailable for 2 participants of the CHS, 64 participants of the MrOS Study, 12 participants of the PAQUID Study, 1 participant of the Rotterdam Study.
- Participants with overt hyperthyroidism among 11 and 8 cohorts, respectively (Figure 1; eFigures 4 and 5 in the Supplement). Participants with overt hyperthyroidism had 0.20 standardized mean difference (95% CI, 0.07 to 0.33; P = .002) higher executive function score compared with participants who were euthyroid; transformed, this would account for 1.6 more correct substitutions within 60 seconds for the LDST based on the largest cohort in this analysis. In both executive function and memory, participants with subclinical hypothyroidism performed better than participants who were euthyroid (executive function: 0.07 standardized mean difference; 95% CI, 0.01 to 0.13; P = .03; memory: 0.08 standardized mean difference; 95% CI, 0.01 to 0.15; P = .03). Longitudinally, no association was found between thyroid dysfunction at baseline and decline in executive function among 7 cohorts or memory among 6 cohorts; all differences were smaller than 0.1 standardized mean difference (Figure 2). Additional adjustment for educational attainment did not materially change the results (eFigure 2 in the Supplement). No statistically significant interaction with sex or age was present (P > .05 for all; supporting data in eTable 3 in the Supplement). Using a fixed-effects model or excluding strata with
fewer than 10 participants did not change the results for executive function or memory (eTable 4 in the Supplement). The association of subclinical hypothyroidism and better executive function was attenuated when participants with missing FT₄ measurements were left out, while the association with memory was unchanged. The positive association between overt hyperthyroidism and executive function disappeared when participants using thyroid medication were removed. No association was found when individuals were categorized by severity of thyrotropin abnormality or when thyrotropin level was analyzed continuously (eFigure 3 and eTable 5 in the Supplement). Continuous analysis of FT₄ levels showed a positive association with executive function (0.019 higher standardized mean difference per SD; 95% CI, 0.002 to 0.036; P = .03), which was attenuated when participants using thyroid medication were left out. Heterogeneity across studies was low for the cross-sectional main analyses (I² = 0%-40%), while heterogeneity was low to moderate for the longitudinal analyses (I² = 0%-70%) and up to high heterogeneity in the sensitivity analyses (I² ≥ 73%).

**Thyroid Dysfunction and Dementia**

Cross-sectional analysis of thyroid dysfunction and dementia were unfeasible owing to few participants who were not eu-

---

**Figure 1. Cross-sectional Association Between Thyroid Dysfunction and Cognitive Function Test Scores**

| Cognitive function by thyroid status | No. of studies | No. of participants | ρ, % | Standardized mean difference (95% CI) | Favors worse cognition | Favors better cognition |
|------------------------------------|----------------|---------------------|-----|--------------------------------------|-----------------------|------------------------|
| **Global cognition**               |                |                     |     |                                      |                       |                        |
| Overt hyperthyroidism              | 16             | 344                 | 0   | -0.06 (-0.20 to 0.08)                |                       |                        |
| Subclinical hyperthyroidism        | 17             | 1492                | 33.34 | -0.02 (-0.09 to 0.04)              |                       |                        |
| Euthyroidism                       | 18             | 31214               | Reference | 0.00 (-0.00 to 0.00)            |                       |                        |
| Subclinical hypothyroidism         | 18             | 2519                | 37.02 | 0.05 (-0.01 to 0.10)               |                       |                        |
| Overt hypothyroidism               | 18             | 345                 | 40.43 | -0.06 (-0.20 to 0.08)              |                       |                        |
| **Executive function**             |                |                     |     |                                      |                       |                        |
| Overt hyperthyroidism              | 9              | 212                 | 0   | 0.20 (0.07 to 0.33)                |                       |                        |
| Subclinical hyperthyroidism        | 10             | 604                 | 0   | -0.04 (-0.12 to 0.04)              |                       |                        |
| Euthyroidism                       | 11             | 17468               | Reference | 0.00 (-0.00 to 0.00)            |                       |                        |
| Subclinical hypothyroidism         | 11             | 1701                | 27.70 | 0.07 (0.01 to 0.13)               |                       |                        |
| Overt hypothyroidism               | 11             | 208                 | 10.15 | -0.05 (-0.20 to 0.09)              |                       |                        |
| **Memory**                         |                |                     |     |                                      |                       |                        |
| Overt hyperthyroidism              | 6              | 144                 | 0   | 0.04 (-0.12 to 0.20)               |                       |                        |
| Subclinical hyperthyroidism        | 7              | 442                 | 0   | -0.07 (-0.15 to 0.01)              |                       |                        |
| Euthyroidism                       | 8              | 11206               | Reference | 0.00 (-0.00 to 0.00)            |                       |                        |
| Subclinical hypothyroidism         | 8              | 745                 | 0   | 0.08 (0.01 to 0.15)               |                       |                        |
| Overt hypothyroidism               | 8              | 140                 | 0.20 | -0.07 (-0.23 to 0.09)              |                       |                        |

---

**Figure 2. Longitudinal Association Between Thyroid Dysfunction and Cognitive Function Test Scores**

| Cognitive function by thyroid status | No. of studies | No. of participants | ρ, % | Standardized mean difference (95% CI) | Favors slower decline | Favors faster decline |
|------------------------------------|----------------|---------------------|-----|--------------------------------------|-----------------------|-----------------------|
| **Global cognition**               |                |                     |     |                                      |                       |                        |
| Overt hyperthyroidism              | 13             | 240                 | 5.02 | 0.03 (-0.10 to 0.16)                |                       |                        |
| Subclinical hyperthyroidism        | 13             | 894                 | 24.50 | -0.02 (-0.10 to 0.06)              |                       |                        |
| Euthyroidism                       | 13             | 18752               | Reference | 0.00 (-0.00 to 0.00)            |                       |                        |
| Subclinical hypothyroidism         | 13             | 1651                | 47.81 | -0.00 (-0.09 to 0.08)              |                       |                        |
| Overt hypothyroidism               | 13             | 242                 | 0    | 0.11 (-0.01 to 0.23)               |                       |                        |
| **Executive function**             |                |                     |     |                                      |                       |                        |
| Overt hyperthyroidism              | 6              | 177                 | 0    | 0.07 (-0.07 to 0.21)               |                       |                        |
| Subclinical hyperthyroidism        | 7              | 436                 | 0    | -0.02 (-0.12 to 0.07)              |                       |                        |
| Euthyroidism                       | 7              | 12368               | Reference | 0.00 (-0.00 to 0.00)            |                       |                        |
| Subclinical hypothyroidism         | 7              | 1156                | 69.48 | -0.02 (-0.15 to 0.11)              |                       |                        |
| Overt hypothyroidism               | 7              | 137                 | 49.42 | 0.02 (-0.23 to 0.26)               |                       |                        |
| **Memory**                         |                |                     |     |                                      |                       |                        |
| Overt hyperthyroidism              | 5              | 122                 | 0    | -0.02 (-0.20 to 0.15)              |                       |                        |
| Subclinical hyperthyroidism        | 6              | 372                 | 0    | -0.07 (-0.17 to 0.02)              |                       |                        |
| Euthyroidism                       | 6              | 9397                | Reference | 0.00 (-0.00 to 0.00)            |                       |                        |
| Subclinical hypothyroidism         | 6              | 643                 | 0    | 0.02 (-0.06 to 0.09)               |                       |                        |
| Overt hypothyroidism               | 6              | 109                 | 0    | -0.07 (-0.25 to 0.11)              |                       |                        |
thyroid with dementia at baseline (78 participants among 11 cohorts). In longitudinal analyses among 12 cohorts, no association was found between thyroid dysfunction and incident dementia (Figure 3; eFigure 6 in the Supplement). The hazard ratio of dementia ranged from 1.54 (95% CI, 0.76 to 3.10) for overt hyperthyroidism to 0.79 (95% CI, 0.48 to 1.28) for overt hypothyroidism. Continuous analysis of thyrotropin and FT₄ levels also did not provide evidence for an association; hazard ratio, 0.96 per SD increase of natural log-transformed thyrotropin (95% CI, 0.91 to 1.02; P = .16); hazard ratio, 1.05 per SD increase of FT₄ (95% CI, 0.98 to 1.13; P = .16). Heterogeneity between studies was low (I² = 0%-40%).

Discussion
In this individual participant data analysis of 74 565 participants from 23 cohorts, there was no association between subclinical thyroid dysfunction and cognitive function, cognitive decline, or the onset of dementia. Owing to uncertainty of the results for overt hypothyroidism and hyperthyroidism, no rigorous conclusions can be drawn regarding the association between overt thyroid dysfunction and cognitive decline and dementia.

While prior study-level meta-analyses also reported no association between subclinical hypothyroidism and cognitive function, cognitive decline, or dementia, they were limited by heterogeneity in definitions of thyroid dysfunction and choices of covariates in the statistical models. Because we performed an individual participant analysis, we could standardize definitions of thyroid function categories and of cognitive function and cognitive decline and standardize the statistical models. By addressing these limitations and reaching the same results, the present study provides the strongest observational evidence to date suggesting that subclinical hypothyroidism is not associated with cognitive function or cognitive decline.

Various studies and 2 meta-analyses did show an association between subclinical or overt hyperthyroidism or low thyrotropin level within the reference range and a higher risk of dementia. Although our findings for subclinical and overt hyperthyroidism and dementia did not reach statistical significance, they are directionally consistent with the literature. Despite combining 8 cohorts comprising more than 45 000 participants, the number of individuals with subclinical and overt hyperthyroidism and the number of individuals who developed dementia during follow-up are limited. Therefore, we cannot exclude a higher risk of dementia in individuals with hyperthyroidism. In addition, individuals with overt hyperthyroidism had a slightly higher rate of cognitive decline, though not statistically significant. Considering the existing literature and the other results in the present study, the observed cross-sectional association between overt hyperthyroidism and better executive function was most likely a chance finding. Moreover, the observed difference in executive function was less than half the minimal clinically important difference, making it a clinically insignificant finding regardless of the P value.

Higher vulnerability among subgroups has been proposed; younger adults and women might be more susceptible to cognitive dysregulation associated with thyroid dysfunction. Moreover, cognitive decline might only be present in individuals with more extreme values of thyrotropin, or variation in FT₄ instead of thyrotropin levels could be associated with dementia risk. In the present multicohort study, we did not observe differential associations for participants younger and older than 75 years or for men and women, nor any association with variation in FT₄ level or more extreme values of thyrotropin. Therefore, subgroup associations reported in prior studies might not be generalizable outside the original cohorts.

As mentioned before, all but 1 randomized clinical trial on levothyroxine treatment for subclinical hypothyroidism also did not provide evidence for improvement of cognitive function. Moreover, both undertreatment and overtreatment with levothyroxine are common, estimated at 27% and 14%, respectively. Overtreatment is associated with increased risk of atrial fibrillation and atherosclerosis and, via cerebrovascular damage, might be associated with increased risk of cognitive decline. Therefore, screening for subclinical thyroid dysfunction in older adults to prevent cognitive impairment and dementia does not appear to be effective.

The current individual participant data analysis has several strengths. The use of individual participant data from cohorts from all over the globe enhances generalization while allowing standardized definitions and relevant subgroup analyses. All but 5 of the included studies had a median age of 70 years or older, which is essential but often not the case in research concerning outcomes that are most relevant for older adults. The present study approached cognition comprehensively; we assessed multiple domains of cognitive function, cross-sectionally and longitudinally, and incidence of dementia.

| Thyroid status            | No. of studies | No. of cases | No. of controls | Hazard ratio (95% CI) | Favors lower risk | Favors higher risk |
|---------------------------|----------------|--------------|-----------------|-----------------------|------------------|-------------------|
| Overt hyperthyroidism     | 3              | 9            | 243             | 1.54 (0.76-3.10)      |                  |                   |
| Subclinical hyperthyroidism | 8              | 86           | 1310            | 1.23 (0.98-1.56)      |                  |                   |
| Euthyroidism              | 8              | 1781         | 40627           | Reference             | 1.00 (1.00-1.00) |                   |
| Subclinical hypothyroidism | 8              | 136          | 1941            | 1.08 (0.91-1.29)      |                  |                   |
| Overt hypothyroidism      | 7              | 21           | 422             | 0.79 (0.48-1.28)      |                  |                   |

Figure 3. Longitudinal Association Between Thyroid Dysfunction and Incident Dementia

Hazard ratios were adjusted for age and sex. Error bars indicate 95% CIs.

The use of individual participant data from cohorts from all over the globe enhances generalization while allowing standardized definitions and relevant subgroup analyses. All but 5 of the included studies had a median age of 70 years or older, which is essential but often not the case in research concerning outcomes that are most relevant for older adults. The present study approached cognition comprehensively; we assessed multiple domains of cognitive function, cross-sectionally and longitudinally, and incidence of dementia.
Limitations

Some limitations need to be acknowledged. Thyroid function categorization was based on biochemical characteristics. For 20% to 30% of the participants who were categorized as subclinical hypothyroid or hyperthyroid, we could not confirm subclinical thyroid dysfunction owing to the absence of FT₄ measurement. This may have led to some misclassification, yet sensitivity analyses excluding those participants with missing FT₄ data yielded similar results. We could not include educational attainment in our main analysis because 5 out of 18 cohorts did not collect these data. Even though the sensitivity analyses with adjustment for educational attainment yielded similar results as the main analysis, education is a possible confounder that could not be accounted for. For most cohorts, only 1 measurement of thyroid function was available, which is why only baseline thyroid function was used in the present individual participant data analysis. This study could therefore not capture any changes in cognitive function that might occur at the transition of one thyroid status to another. Moreover, for the vast majority of study participants, a maximum of 2 measurements of cognitive function was available, which precluded advanced modeling of change over time including nonlinear trajectories. In addition, the interpretation of longitudinal studies of cognitive function can be complicated by practice effects. Standardization of change over time might not fully alleviate this; hence, residual practice effects may still be present. Furthermore, because dementia is clinically difficult to diagnose, some misclassification could have occurred, which may have led to an underestimation of the association. In addition, the number of incident dementia cases in the included cohort studies was low; we therefore cannot rule out a clinically relevant association between thyroid dysfunction and risk of dementia. The heterogeneity between studies may have been increased by the use of different cognitive function tests, different durations of follow-up, differences in age and sex distribution, different lifestyles across continents, and different inclusion criteria. As heterogeneity was expected a priori, we performed all meta-analyses with random effects. Nonetheless, results for fixed-effects meta-analyses were not materially different. The observed heterogeneity was larger in the longitudinal analyses heterogeneity ($I^2 = 0\%-70\%$) than in the cross-sectional analyses ($I^2 = 0\%-40\%$), likely owing to the additional variation of follow-up duration. We hypothesize that the minor differences in $I^2$ estimates between different cross-sectional analyses are attributable to differences in sample size per exposure. Because individuals with thyroid disease generally receive medical treatment, we cannot address the question of whether long-term untreated hyperthyroidism or hypothyroidism is associated with cognitive function and dementia risk. Moreover, these results only apply to objectifiable cognitive decline, which is not synonymous with the more subjective cognitive complaints.

Conclusions

In this individual participant data analysis combining the individual participant data of 74,565 participants from 23 cohorts, subclinical thyroid dysfunction was not associated with cognitive function, cognitive decline, or risk of dementia. Hence, it is unlikely that treatment for otherwise undetected subclinical thyroid dysfunction would improve cognitive function. Moreover, the chance of overtreatment is considerable, which increases the risk of atrial fibrillation, atherosclerosis, and cerebral infarction and thereby might increase the risk of cognitive decline. Whether treatment of overt hypothyroidism or hyperthyroidism is associated with cognitive decline and risk of dementia remains uncertain. Existing clinical guidelines that prescribe screening of subclinical thyroid dysfunction for prevention of cognitive decline or dementia should therefore be revisited.
Amsterdam UMC, Amsterdam, the Netherlands (Den Elzen); Longitudinal Studies Section, Translational Gerontology Branch, Harbor Hospital, Baltimore, Maryland (Ferrucci); National Institute on Aging NIA-ASTRA Unit, Baltimore, Maryland (Ferrucci); Geriatric Research Education and Clinical Center, VA Healthcare System, Minneapolis, Minnesota (Fink); Department of Medicine, University of Minnesota, Minneapolis (Fink); Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany (Grab); German Center for Neurodegenerative Diseases (DZNE), Site Rostock/Greifswald, Germany (Grab); Department of Epidemiology and Biostatistics, Amsterdam Public Health Research Institute, Amsterdam UMC, VU University Amsterdam, Amsterdam, the Netherlands (Huisman); Department of Sociology, VU University Amsterdam, Amsterdam, the Netherlands (Huisman); Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands (Schulz); Department of Clinical Studies, Radiation Effects Research Foundation, Hiroshima and Nagasaki, Japan (Imaiuizumi, Yamada); Department of Internal Medicine and Endocrinology, Amsterdam UMC, Amsterdam, the Netherlands (de Jongh); Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands (Jukema); Netherlands Heart Institute, Utrecht, the Netherlands (Jukema); Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, South Korea (Kim); Department of Psychiatry, Seoul National University College of Medicine, Seoul, South Korea (Kim); Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania (Kuller); Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (Lopez); Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea (Moon); Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany (Nauck); DZHK (German Centre for Cardiovascular Research), partner site, Greifswald, Germany (Nauck); Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom (Parle); Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands (Peeters); Academic Center for Thyroid Diseases, Erasmus MC, Rotterdam, the Netherlands (Peeters); Division of Endocrinology, Diabetes and Clinical Nutrition, Department of Medicine, Oregon Health & Science University, Portland (Samuels); Department of Radiology, University Medicine Greifswald, Greifswald, Germany (Schmidt); Department of Neurology, University Medicine Greifswald, Greifswald, Germany (Schmidt); Department of Biomedical Data Sciences, Section of Molecular Epidemiology, Leiden University Medical Center, Leiden, the Netherlands (Slagboom); Max Planck Institute for Biology of Ageing, Cologne, Germany (Slagboom); Namsos Hospital, Nord-Trøndelag Hospital Trust, Namsos, Norway (Stordal); Department of Mental Health, NTNU, Norwegian University of Science and Technology, Trondheim, Norway (Stordal); Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany (Völzke); Department of Public Health, Section of Epidemiology, Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark (Westendorp); Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Western Australia, Australia (Yeap); Department of Public Health and Primary Care, University Medical Center, Leiden, the Netherlands (Gussekloo).

Author Contributions: Drs van Vliet and Trompet had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: van Vliet, Blauw, Comijs, Dartigues, den Elzen, Imaizumi, Mooijaart, Stordal, Westendorp, Gussekloo. Acquisition, analysis, or interpretation of data: van Vliet, van Heemst, Almeida, Æsbøl, Aurbet, Bae, Barnes, Bauer, Bayeu, Cappola, Ceresini, Dartigues, Degryse, Dullaart, van Eersel, den Elzen, Ferrucci, Flicker, Grabe, Han, Helmer, Huisman, Ikram, Imaizumi, de Jongh, Jukema, Kim, Kuller, Lopez, Mooijaart, Moon, Mouzouri, Nauck, Parle, Peeters, Samuels, Schmidt, Schminke, Slagboom, Sloag, Völzke, Westendorp, Yamada, Yeap, Rodondi, Trompet.

Drafting of the manuscript: van Vliet, Barnes, Comijs, Dullaart, Mooijaart.

Critical revision of the manuscript for important intellectual content: van Vliet, van Heemst, Almeida, Æsbøl, Aurbet, Bae, Bauer, Blauw, Bayeu, Cappola, Ceresini, Dartigues, Degryse, van Eersel, den Elzen, Ferrucci, Flicker, Grabe, Han, Helmer, Huisman, Ikram, Imaizumi, de Jongh, Jukema, Kim, Kuller, Lopez, Mooijaart, Moon, Mouzouri, Nauck, Parle, Peeters, Samuels, Schmidt, Schminke, Slagboom, Stordal, Vols, Völzke, Westendorp, Yamada, Yeap, Rodondi, Gussekloo, Trompet.

Statistical analysis: van Vliet, Gussekloo.

Obtained funding: van Vliet, Almeida, Barnes, Comijs, Dartigues, Degryse, Dullaart, Flicker, Grabe, Helmer, Ikram, Jukema, Kim, Mooijaart, Spaans, Stordal, Vols, Völzke, Westendorp, Yamada, Yeap, Rodondi, Gussekloo, Trompet.

Administrative, technical, or material support: Bae, Barnes, Ceresini, Comijs, Dartigues, Dullaart, den Elzen, Flicker, Han, Kim, Moon, Mouzouri, Nauck, Peeters, Slagboom, Stordal, Vols, Völzke, Yamada, Yeap, Rodondi.

Supervision: van Heemst, Blauw, van Eersel, Grabe, Ikram, Jukema, Kim, Lopez, Mooijaart, Westendorp, Gussekloo, Trompet.

Conflict of Interest Disclosures: Dr van Vliet reported grants from European Commission Horizon 2020 programs during the conduct of the study. Dr van Heemst reported grants from European Commission during the conduct of the study; grants from Velux Stiftung (grant No. 1156) outside the submitted work. Dr Lopez reported personal fees for consulting from Biogen and Grifols outside the submitted work. Dr Maus equally reported nonfinancial support (provision of medication free of charge) from Merck during the conduct of the study. Dr Nauck reported grants from Federal Ministry of Education and Research, Germany, European Union Interreg VA grants no. 01ZZ9603, 01ZZ2013, 01ZZ2043, B12740D717, B12740D717, INT-10-G008; personal fees for advisory boards and presentations from Radiometer, Becton Dickinson, AstraZeneca, Technopath Clinical Diagnostics, Novartis, Symex, Tosoh, medpoint Medizinkommunikations GmbH, ProteinT, and MDI Lumbach; and travel/ accommodations expenses covered or reimbursed from German Medical Association (BÄK), German Centre for Cardiovascular Research (GCCR), National Cohort, German Society for Clinical Chemistry and Laboratory Medicine e.V. (DGKL), ISBER, DAkkS, Deutsche Forschungsgemeinschaft (DFG), European Association for the Study of Diabetes (EASD), and Max Rubner-Institut outside the submitted work. Dr Yeap reported grants from National Health and Medical Research Council of Australia during the conduct of the study. Dr Rodondi reported grants from Swiss National Science Foundation during the conduct of the study. No other disclosures were reported.

Funding/Support: This work was supported by the European Commission project THYRAGE (Horizon 2020 research and innovation program, 668689). The Thyroid Studies Collaboration is funded by a grant from the Swiss National Science Foundation (SNF 320030-172676 to Dr Rodondi). This research was supported by contracts N01-HC85079, N01-HC85080, N01-HC85081, N01-HC85082, N01-HC85083, N01-HC85084, N01-HC85085, N01-HC85086, 5SN0920190006, and grants U01HL08299 and U01HL083074 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by RO1AG203629 from the National Institute on Aging. Dr Cappola received additional support from RO1AG207058, Dr Kuller from RO1AG19928, and Dr Lopez from RO1AG0938. A full list of principal investigators and institutions can be found at https://chs-nhlbi.org/. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). This research was supported by National Institute on Aging contracts NO1-AG-6-2101, NO1-AG-6-2103, NO1-AG-6-2106, National Institute on Aging grant RO1-AG20850, and National Institute of Nursing Research grant RO1-NR012459. This research was funded in part by the Intramural Research Program of the NIH National Institute on Aging. The Translational Health Study (The HUNT Study) is a collaboration between HUNT Research Centre (Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology), Trøndelag County Council, Central Norway Regional Health Authority, and the Norwegian Institute of Public Health. Information on incident dementia diagnoses for the HUNT study population was provided by Nord-Trøndelag Hospital Trust. The INCHANTI study was supported as a “targeted project” (ICST10/1RF97.7) by the Italian Ministry of Health and in part by the US National Institute on Aging (contracts: 263 MD).
Association of Thyroid Dysfunction With Cognitive Function

Original Investigation Research

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Participating Studies of the Thyroid Studies Collaboration: United States: Cardiovascular Health Study, Health, Aging, and Body Composition Study; and the Osteoporotic Fractures in Men (MrOS) Study. Norway: Nord-Trøndelag Health Study (HUNT Study). The Netherlands: Leiden 85-Plus Study. Prevention of Renal and Vascular End-stage Disease Study (PREVEND Study); and the Rotterdam Study. The Netherlands/Ireland/Scotland: Prospective Study of Pravastatin in the Elderly at Risk (PROSPER Study). Italy: Invecchiare in Chianti (InChIANT Study) Belgium: BELFRAIL Study. Germany: Study of Health in Pomerania (SHIP). Australia: Health in Men Study. Japan: Nagasaki Adult Health Study (Radiation Effects Research Foundation, RERF). Republic of Korea: Korean Longitudinal Study on Cognitive Aging and Dementia (KLOSA); and Korean Longitudinal Study on Health and Aging (KLSHA).

Additional Contributions: We thank all study participants for making this study possible. We thank Lila Cárdenas-Ibarra, MD, for providing data from the Mexican Memory Clinic; she was compensated for this contribution.

REFERENCES

1. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based report) of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-1153. doi:10.1212/WNL.56.9.1143
2. Sorbi S, Hort J, Erkinjuntti T, et al; EFNS President Panel on Dementia and Cognitive Neurology. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012;19(9):1519-1530. doi:10.1111/j.1468-1331.2012.03784.x
3. Cognitive Decline Partnership Centre. Clinical practice guidelines and principles for people with dementia. Published February 2016. Accessed August 2, 2021. https://cfpc.sydney.edu.au/research/cultural-guidelines-for-dementia/
4. Luqmanian W, Petcharit C, Srinoprasert V. Prevalence of potentially reversable conditions in dementia and mild cognitive impairment in a geriatric clinic. Geriatr Gerontol Int. 2012;12(4):59-64. doi:10.1111/j.1447-0594.2011.00728.x
5. Ritchie M, Yeap BB. Thyroid hormone: influences on mood and cognition in adults. Motatins. 2015;81(2):266-275. doi:10.1610/maturitas.2015.03016
6. Vogel A, Elberling TV, Harding M, et al. Affective symptoms and cognitive functions in the acute phase of Graves’ thyroidosis. Psychoneuroendocrinology. 2007;32(1):36-43. doi:10.1016/j.psyneuen.2006.09.012
7. Welking EM, Appelhof BC, Fliers E, et al. Cognitive functioning and well-being in euthyroid patients on thyroid replacement therapy for primary hypothyroidism. Eur J Endocrinol. 2005;153(6):747-753. doi:10.1530/eje.0.102025
8. Jorde R, Waterko H, Storhaug H, Nyrnes A, Sundsfjord J, Jassen TG. Neuropsychological phenomena used by subject with subclinical hypothyroidism and the effect of thyroid therapy. J Clin Endocrinol Metab. 2006;91(1):145-153. doi:10.1210/jc.2005-2175
9. Parie J, Roberts L, Wilson S, et al. Randomized controlled trial of the effect of levothyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid study. J Clin Endocrinol Metab. 2010;95(8):3623-3632. doi:10.1210/jc.2009-2571
10. Stott DJ, Roddon N, Kearney PM, et al; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(24):2354-2364. doi:10.1056/NEJMoa1603825
11. Moijaart SP, Du Puy RS, Stott DJ, et al. Association between levothyroxine treatment and thyroid-related symptoms among adults aged 80 years and older with subclinical hypothyroidism. JAMA. 2019;322(20):1977-1986. doi:10.1001/jama.2019.7274
12. Ahlgir R, Khansheh ME, Malek M, et al. Changes of subtests of Wechsler Memory Scale and cognitive function in subjects with subclinical hypothyroidism following treatment with levothyroxine. Arch Med Sci. 2012;8(6):1096-1101. doi:10.5137/ams.2012.32423
13. Feller M, Snell M, Moutouzoi E, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA. 2018;320(13):1349-1359. doi:10.1001/jama.2018.13770
14. Rieben C, Segna D, da Costa BR, et al. Subclinical thyroid dysfunction and the risk of cognitive decline: a meta-analysis of prospective cohort studies. J Clin Endocrinol Metab. 2016;101(12):4945-4954. doi:10.1210/jc.2016-2129
15. Akintola AA, Jansen SW, van Bodegom D, et al. Subclinical hypothyroidism and cognitive function in people over 60 years: a systematic review and meta-analysis. Front Aging Neurosci. 2015;7:150. doi:10.3389/fnagi.2015.00050
16. Pasqualetti G, Pagano G, Rengo G, Ferrara N, Monzani F. Subclinical hypothyroidism and cognitive impairment: systematic review and meta-analysis. J Clin Endocrinol Metab. 2015;100(11):4240-4245. doi:10.1210/jc.2015-2046
17. Wu Y, Pei W, Yang F, Xu D, Oli W. Higher FT4 or TSH below the normal range are associated with increased risk of dementia: a meta-analysis of 11 studies. Sci Rep. 2016;6:31975. doi:10.1038/srep31975
18. Rodoniti N, den Elzen WP, Bauer DC, et al; Thyroid Studies Collaboration. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;303(12):1365-1374. doi:10.1001/jama.2010.1361
19. Vaes B, Pasquet A, Wallacpe M, et al. The BELFRAIL (BF_caron); study: a population-based prospective cohort study of the very elderly in Belgium. BMC Geriatr. 2010;10:39. doi:10.1186/1471-2389-10-39
20. Cappola AR, Arnold AM, Wulczyn K, Carlson M, Robbins J, Pissay BM. Thyroid function in the euthyroid range and adverse outcomes in older adults. J Clin Endocrinol Metab. 2015;100(3):1088-1096. doi:10.1210/jc.2014-3586
21. Aubert CE, Bauer DC, da Costa BR, et al; Health ABC Study. The association between subclinical thyroid dysfunction and dementia: the Health, Aging and Body Composition (Health ABC Study. J Clin Endocrinol (Octf). 2017;87(5):617-626. doi:10.1.1016/j.cen.2015.03.016
22. Yeap BB, Alfonso H, Chubb SA, et al. Higher free thyroid levels predict increased incidence of dementia in older men. J Clin Endocrinol Metab. 2012;97(12):E2230-E2237. doi:10.1210/jc.2012-2108
23. Bjero T, Holmen J, Krüger O, et al; The Health Study of Nord-Trondelag (HUNT). Prevalence of thyroid disease, thyroid dysfunction and thyroid hormone antibodies in a large, unselected population. Eur J Endocrinol. 2000;143(5):639-647. doi:10.1530/eje.01.1430639
24. Ceresini G, Laurentini F, Maggio M, et al. Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J Am Geriatr Soc. 2009;57(7):989-93. doi:10.1111/j.1532-5415.2008.02080.x
25. Han JW, Kim TH, Kwak KP, et al; Overview of the Korean longitudinal study on cognitive aging and dementia. Psychiatry Investig. 2018;15(8):767-774. doi:10.7373/pi.2018.06026
26. Moon JH, Park YJ, Kim TH, et al. Lower but-normal serum TSH level is associated with the development or progression of cognitive impairment in elderly: Korean Longitudinal Study on Health and Aging (KLSHA). J Clin Endocrinol Metab. 2014;99(2):424-432. doi:10.1210/jc.2013-3385
27. Gussélkø J, van Exel E, de Craen AJ, Meinders AE, Frolisch M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292(21):2591-2599. doi:10.1001/jama.292.21.2591
Thyroid function and cognitive decline in the elderly. Endocrinology. 2008;149(2):270-278.

Dubey DK, Tripathi CB. A cross-sectional study on the association of thyroid function in elderly with cognitive function. Arch Gerontol Geriatr. 2008;46(2):173-180. doi:10.1016/j.archger.2007.03.009

Manciet G, Dartigues JF, Decamps A, et al. The cognitive function in elderly: six-year observational longitudinal examination survey: plan and operations, methods and results. Psychoneuroendocrinology. 2008;33(7):1031-1022. doi:10.1016/j.psyneuen.2008.05.008

de Jongh RT, Lips P, van Schoor NM, et al. Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. Eur J Endocrinol. 2011;165(4):545-554. doi:10.1530/EJE-11-0430

Schonenmaker M, de Craen AJ, de Meijer PH, et al. Evidence of genetic enrichment for exceptional survival using a family approach: the Leiden Longevity Study. Eur J Hum Genet. 2006;14(1):79-84. doi:10.1038/sj.ejhg.5502108

Cárdenas-ibarra L, Solano-Velázquez JA, Salinas-Martínez R, Aspera-Ledesma TD, Sifuentes-Martínez MdeR, Villarreal-Pérez JZ. Cross-sectional observations of thyroid function in geriatric Mexican outpatients with and without dementia. Arch Gerontol Geriatr. 2008;46(2):173-180. doi:10.1016/j.archger.2007.03.009

Maniet G, Dartigues JF, Decamps A, et al. The PAQUID survey and correlates of subclinical hyperthyroidism in elderly community residents in the southwest of France. Age Ageing. 1995;24(3):235-241. doi:10.1093/ageing/24.3.235

Zipf G, Chiappa M, Porter KS, Ostchega Y, Dubey DK, Tripathi CB, van der Elst W, van Boxtel MPJ, van Breukelen GJCM, Slagter SN, Muller Kobold AC, Chaker L, Baumgartner C, den Elzen WP, et al. Visuele Associatie Test (VAT). A cross-sectional study on thyroid status in North Indian elderly outpatients with dementia. Ann Indian Acad Neurol. 2013;16(3):333-337. doi:10.4103/0972-2371.106916

Winkler A, Weimar C, Jöckel KH, et al. Thyroid-stimulating hormone and mild cognitive impairment: results of the Heinz Nixdorf Recall Study. J Alzheimers Dis. 2016;49(3):797-807. doi:10.3233/JAD-150561

Chachamovitz DS, Vigario Pddos, Silva SO, et al. Does low-normal serum TSH level adversely impact cognition in elderly adults and might methimazole therapy improve outcomes? Endocr J. 2015;63:495-505. doi:10.1507/endocrj.EJ5-0458

Wouters HJCM, Slater SN, Muller Kobold AC, van der Klauw MM, Wolfenbuttel BHR. Epidemiology of thyroid disorders in the Lifelines Cohort Study (the Netherlands). PLoS One. 2020;15(11):e0242795. doi:10.1371/journal.pone.0242795

Chaker L, Baumgartner C, den Elzen WP, et al; Thyroid Studies Collaboration. Thyroid function within the reference range and the risk of stroke: an individual participant data analysis. J Clin Endocrinol Metab. 2016;101(11):4270-4282. doi:10.1210/jc.2016-2255

Bano A, Chaker L, Mattace-Raso FUS, et al. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: the Rotterdam Study. Circ Res. 2017;121(2):1392-1400. doi:10.1161/CIRCRESAHA.117.316103

Mooijaart SP, Broekhuizen K, Trompet S, et al. Evidence-based medicine in older patients: how can we do better? Neth J Med. 2015;73(5):211-218.

Calamia M, Markon K, Tranell D. Scoring higher for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database Syst Rev. 2016(10).doi:10.1002/14651858.CD001145.pub2

Research

Association of Thyroid Dysfunction With Cognitive Function